GLP-1 Agonists in Uncharted Territory: What Prescribers Must Know About Expanded Indications, Coverage Gaps, and Ethical Practice in 2024

Few drug classes have reshaped clinical conversations — and patient expectations — as rapidly as glucagon-like peptide-1 (GLP-1) receptor agonists. Originally approved as adjunctive agents for glycemic control in type 2 diabetes, drugs such as semaglutide, liraglutide, dulaglutide, and tirzepatide (a dual GIP/GLP-1 agonist) have accumulated a body of evidence extending well beyond endocrinology. Cardiovascular outcomes trials, emerging data in metabolic dysfunction-associated steatohepatitis (MASH), early signals in addiction medicine, and robust weight-loss efficacy in non-diabetic patients have collectively positioned GLP-1 agonists at the center of one of the most consequential prescribing debates in recent US healthcare.

For the prescribing clinician, this landscape presents both opportunity and obligation. Understanding precisely where FDA approval ends and off-label territory begins — and what that distinction requires in practice — is no longer optional knowledge.

What the FDA Has Actually Approved

Clarity on approved indications is the necessary starting point for any discussion of expanded use.

Semaglutide is currently approved under two distinct branded formulations with meaningfully different indications. Ozempic (semaglutide injection, Novo Nordisk) carries approval for glycemic management in adults with type 2 diabetes and, following the landmark SELECT trial, for reduction of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and either obesity or overweight — regardless of diabetes status. Wegovy (semaglutide injection, higher dose formulation) is approved specifically for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity.

Tirzepatide follows a similar bifurcated structure. Mounjaro (tirzepatide, Eli Lilly) is approved for type 2 diabetes management, while Zepbound carries the chronic weight management indication under criteria comparable to Wegovy.

Liraglutide (Victoza for diabetes; Saxenda for weight management) and dulaglutide (Trulicity) round out the class with their respective approved uses. Prescribers should note that interchanging branded formulations — using Ozempic for weight management in a non-diabetic patient, for instance — constitutes off-label prescribing, irrespective of the shared active ingredient.

The Off-Label Reality: Clinical Evidence and Patient Demand

Off-label prescribing is legal, common, and sometimes clinically well-supported in the United States. The FDA explicitly does not regulate the practice of medicine, and physicians retain the authority to prescribe approved drugs for unapproved uses when sound clinical judgment supports doing so. What off-label prescribing does require, however, is a defensible evidence base, transparent patient communication, and thorough documentation.

The clinical evidence for GLP-1 agonists in several off-label contexts has matured considerably. In non-alcoholic fatty liver disease and its more severe form, MASH, semaglutide has demonstrated histological improvement in phase II trials, with phase III data from the ESSENCE trial now informing evolving prescribing practice. In polycystic ovary syndrome (PCOS), GLP-1 agents are being used off-label to address insulin resistance and weight, with supportive — if not yet definitive — observational data. Perhaps most provocatively, early research in alcohol use disorder and other addictive behaviors has generated significant interest, though the evidence base remains insufficient to support routine clinical application at this time.

The demand side of this equation is equally significant. Patients are arriving at appointments with substantial awareness — and sometimes unrealistic expectations — shaped by media coverage, social platforms, and peer networks. Clinicians are frequently navigating a gap between what patients have read and what the evidence actually supports.

Insurance Coverage: A Fragmented and Rapidly Shifting Landscape

Perhaps no aspect of GLP-1 prescribing generates more friction in clinical practice than insurance coverage — and the landscape in 2024 remains deeply inconsistent across payers, plan types, and states.

Medicare's exclusion of weight-loss drugs under Part D — a restriction rooted in legislation predating the current generation of anti-obesity medications — remains a significant barrier for older patients. The Treat and Reduce Obesity Act, which would amend this exclusion, has been reintroduced in Congress multiple times without passage, leaving Medicare beneficiaries largely without coverage for Wegovy or Zepbound unless a covered cardiovascular indication applies. The SELECT trial data supporting Ozempic for MACE reduction in non-diabetic patients with obesity and cardiovascular disease has opened a narrow but meaningful coverage pathway for some Medicare patients, and prescribers should be familiar with this indication when clinically appropriate.

Medicaid coverage varies substantially by state. Some states have implemented prior authorization requirements with strict BMI and comorbidity thresholds; others have effectively excluded GLP-1 weight-management agents from formularies altogether due to budget pressures. Commercial plans have similarly moved in divergent directions, with some large employers adding coverage in response to workforce health data while others have imposed quantity limits or step-therapy requirements mandating trial of other agents first.

For prescribers, this variability has practical implications. Prior authorization submissions for GLP-1 agents require precise clinical documentation — confirmed BMI, documented comorbidities, record of prior weight-management interventions, and, where applicable, cardiovascular risk stratification. Incomplete documentation is among the most common causes of denial, and appeals that include robust clinical narratives significantly improve success rates.

Ethical Prescribing: Informed Consent and Equity Considerations

The ethics of GLP-1 prescribing in 2024 extend in two directions: the obligations owed to individual patients and the broader questions of equitable access.

At the individual level, informed consent for off-label GLP-1 use should address several specific elements: the distinction between the prescribed formulation's approved indication and the intended use, the nature and quality of supporting evidence, known adverse effects (including gastrointestinal tolerability, rare risks of pancreatitis, and the still-evolving data on thyroid C-cell tumors in humans), the anticipated duration of therapy given that weight regain following discontinuation is well-documented, and the financial implications if insurance coverage is denied or discontinued.

This last point carries particular weight. Patients who initiate GLP-1 therapy under commercial coverage may face abrupt discontinuation if employment changes, plan formularies shift, or prior authorization is not renewed. Clinicians have an ethical obligation to discuss this possibility prospectively, ensuring that treatment plans do not create dependency on a therapy that may become financially inaccessible.

At the population level, the current distribution of GLP-1 access raises legitimate equity concerns. Shortages that persisted through 2023 and into 2024, driven in part by off-label demand, disproportionately affected patients with type 2 diabetes who depend on these agents for glycemic control. Prescribers should weigh the clinical urgency of initiating therapy in non-diabetic patients during periods of constrained supply. Professional societies, including the Obesity Medicine Association and the American Diabetes Association, have issued guidance encouraging priority access for patients with established medical indications during shortage conditions.

Documentation Standards That Protect Prescribers and Patients

For clinicians prescribing GLP-1 agonists — whether on-label or off — documentation quality is both a legal safeguard and a continuity-of-care tool.

Best-practice documentation for GLP-1 prescribing should include: the specific clinical indication and its relationship to the prescribed formulation's approval status; objective baseline data (weight, BMI, HbA1c where applicable, cardiovascular risk factors); the evidence or clinical rationale supporting the prescribing decision; the informed consent discussion, including off-label status where relevant; a monitoring plan with defined endpoints; and a plan for reassessment if clinical response is inadequate or adverse effects emerge.

This level of documentation supports prior authorization submissions, provides a foundation for appeals, and creates a defensible record should a prescribing decision ever be scrutinized in a liability context.

Looking Ahead

The GLP-1 receptor agonist class will almost certainly expand further in the coming years. Oral semaglutide formulations, combination agents targeting additional metabolic pathways, and potential approvals in MASH, heart failure with preserved ejection fraction, and possibly sleep apnea are all in active development or regulatory review. Each new approval will reset the boundary between standard and off-label use, requiring prescribers to remain current.

For now, the most effective clinical posture combines openness to the evidence with rigor in application — prescribing where the data supports it, communicating honestly where it does not, and advocating for the coverage structures that allow patients to benefit from one of the most therapeutically significant drug classes to emerge in a generation.